A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or = 1 Conventional Synthetic DMARD
Phase of Trial: Phase IV
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms APTITUDE; FOREMOST
- Sponsors Celgene Corporation
- 12 Aug 2019 Planned End Date changed from 29 Jan 2021 to 12 Aug 2021.
- 12 Aug 2019 Planned primary completion date changed from 17 Jul 2020 to 28 Jan 2021.
- 18 Dec 2018 Planned End Date changed from 31 Mar 2021 to 29 Jan 2021.